Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy

被引:45
|
作者
Solberg, Timothy D. [2 ]
Nearman, Jessica
Mullins, John
Li, Sicong
Baranowska-Kortylewicz, Janina [1 ]
机构
[1] Univ Nebraska Med Ctr, Dept Radiat Oncol, Omaha, NE 68198 USA
[2] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 72卷 / 03期
关键词
stereotactic body radiotherapy; vascular endothelial growth factor; VEGF; VEGFR2; osteopontin;
D O I
10.1016/j.ijrobp.2008.06.1925
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the late effects of radiotherapy (RT) on vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR2), and osteopontin (OPN) expression in cancer and stromal cells. Methods and Materials: LS174T xenografted athymic mice were used as a tumor model. Radiation was delivered in two equivalent fractionation schemes: 5 x 7 Gy and 1 x 20 Gy, the latter at two dose rates. Results: Tumor growth arrest was similar in all treatment groups, with the exception of a better response of small-size tumors in the 5 x 7-Gy group. The host VEGF and OPN levels were directly proportional to the tumor doubling time and were independent of the fractionation scheme. The host and cancer cell VEGFR2 levels in tumor were also directly related to the tumor response to RT. Conclusion: Upregulated VEGFR2 in cancer cells suggest paracrine signaling in the VEGFR2 pathway of cancer cells as the factor contributing to RT failure. The transient activation of the host VEGF/VEGFR2 pathway in tumor supports the model of angiogenic regeneration and suggests that radiation-induced upregulation of VEGF, VEGFR2,and downstream proteins might contribute to RT failure by escalating the rate of vascular repair. Coexpression of host OPN and VEGF, two factors closely associated with angiogenesis, indicate that OPN can serve as a surrogate marker of tumor recovery after RT. Taken together, these results strongly support the notion that to achieve optimal therapeutic outcomes, the scheduling of RT and antiangiogenic therapies will require patient-specific post-treatment monitoring of the VEGF/NIEGFR2 pathway and that tumor-associated OPN can serve as an indicator of tumor regrowth. (C) 2008 Elsevier Inc.
引用
收藏
页码:918 / 926
页数:9
相关论文
共 50 条
  • [1] VEGF, VEGFR2 and HIF-1α expression in circulating tumor cells (CTCs) of breast cancer patients
    Kallergi, G.
    Agelaki, S.
    Gannoukaraki, V
    Markomanolaki, H.
    Lianidou, E.
    Mavroudis, D.
    Georgoulias, V
    CANCER RESEARCH, 2009, 69 (02) : 114S - 114S
  • [2] Expression of VEGF and Its receptors VEGFR1/VEGFR2 Is Associated with Invasiveness of Bladder Cancer
    Kopparapu, Pradeep Kumar
    Boorjian, Stephen A.
    Robinson, Brian D.
    Downes, Martin
    Gudas, Lorraine J.
    Mongan, Nigel P.
    Persson, Jenny L.
    ANTICANCER RESEARCH, 2013, 33 (06) : 2381 - 2390
  • [3] Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer
    E. A. Kim
    E. S. Gershtein
    I. V. Vysotskaya
    N. E. Kushlinskii
    Bulletin of Experimental Biology and Medicine, 2008, 145 : 245 - 248
  • [4] Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer
    Kim, E. A.
    Gershtein, E. S.
    Vysotskaya, I. V.
    Kushlinskii, N. E.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2008, 145 (02) : 245 - 248
  • [5] MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway
    E Lorenzon
    R Colladel
    E Andreuzzi
    S Marastoni
    F Todaro
    M Schiappacassi
    G Ligresti
    A Colombatti
    M Mongiat
    Oncogene, 2012, 31 : 3136 - 3147
  • [6] MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway
    Lorenzon, E.
    Colladel, R.
    Andreuzzi, E.
    Marastoni, S.
    Todaro, F.
    Schiappacassi, M.
    Ligresti, G.
    Colombatti, A.
    Mongiat, M.
    ONCOGENE, 2012, 31 (26) : 3136 - 3147
  • [7] Tumor Specific VEGF-A and VEGFR2/KDR Protein are Co-expressed in Breast Cancer
    Lisa Rydén
    Barbro Linderholm
    Niels Hilmer Nielsen
    Stefan Emdin
    Per-Ebbe Jönsson
    Göran Landberg
    Breast Cancer Research and Treatment, 2003, 82 : 147 - 154
  • [8] Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
    Chatterjee, Sampurna
    Heukamp, Lukas C.
    Sioba, Maike
    Schoettle, Jakob
    Wieczorek, Caroline
    Peifer, Martin
    Frasca, Davide
    Koker, Mirjam
    Koenig, Katharina
    Meder, Lydia
    Rauh, Daniel
    Buettner, Reinhard
    Wolf, Juergen
    Brekken, Rolf A.
    Neumaier, Bernd
    Christofori, Gerhard
    Thomas, Roman K.
    Ulrich, Roland T.
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (04): : 1732 - 1740
  • [9] Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer
    Rydén, L
    Linderholm, B
    Nielsen, NH
    Emdin, S
    Jönsson, PE
    Landberg, G
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (03) : 147 - 154
  • [10] VEGF and VEGF receptor-2 (VEGFR2) gene polymorphisms predict tumor recurrence in stage II and III colon cancer
    Lurje, G.
    Schultheis, A. M.
    Hendifar, A. E.
    Ashouri, S.
    Zhang, W.
    Gordon, M. A.
    Nagashima, F.
    Chang, H. M.
    Yang, D.
    Lenz, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)